Clinical Research of Calorad®
& Collagen
Role of Collagen Hydrolysate in Bone and Joint Disease.
Moskowitz RW.
Case Western Reserve University, Division of Rheumatic
Diseases, University Hospitals of Cleveland, OH, USA.
Objectives
To review the current status of collagen hydrolysate in
the treatment of osteoarthritis and osteoporosis.
Methods
Review of past and current literature relative to collagen
hydrolysate metabolism, and assessment of clinical investigations
of therapeutic trials in osteoarthritis and osteoporosis.
Results
Hydrolyzed gelatin products have long been used in pharmaceuticals
and foods; these products are generally recognized as
safe food products by regulatory agencies. Pharmaceutical-grade
collagen hydrolysate (PCH) is obtained by hydrolysis of
pharmaceutical gelatin. Clinical studies suggest that
the ingestion of 10 g PCH daily reduces pain in patients
with osteoarthritis of the knee or hip; blood concentration
of hydroxyproline is increased. Clinical use is associated
with minimal adverse effects, mainly gastrointestinal,
characterized by fullness or unpleasant taste. In a multicenter,
randomized, doubleblind, placebo-controlled trial performed
in clinics in the United States, United Kingdom, and Germany,
results showed no statistically significant differences
for the total study group (all sites) for differences
of mean pain score for pain. There was, however, a significant
treatment advantage of PCH over placebo in German sites.
In addition, increased efficacy for PCH as compared to
placebo was observed in the overall study population amongst
patients with more severe symptomatology at study onset.
Preferential accumulation of 14C-labeled gelatin hydrolysate
in cartilage as compared with administration of 14C-labeled
proline has been reported. This preferential uptake by
cartilage suggests that PCH may have a salutary effect
on cartilage metabolism.
Given the important role for collagen in bone structure,
the effect of PCH on bone metabolism in osteoporotic persons
has been evaluated. Studies of the effects of calcitonin
with and without a collagen hydrolysate-rich diet suggested
that calcitonin plus PCH had a greater effect in inhibiting
bone collagen breakdown than calcitonin alone, as characterized
by a fall in levels of urinary pyridinoline cross-links.
PCH appeared to have an additive effect relative to use
of calcitonin alone.
Conclusion
Collagen hydrolysate is of interest as a therapeutic agent
of potential utility in the treatment of osteoarthritis
and osteoporosis. Its high level of safety makes it attractive
as an agent for long-term use in these chronic disorders.
Publication Types:
- Clinical Trial
- Multicenter Study
- Randomized Controlled Trial
|
